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Familial Hypercholesterolemia (FH) is the most common and serious monogenic disorder of 
lipoprotein metabolism that leads to premature coronary heart disease. There are over 65,000 people 
estimated to have FH in Australia, but many remain undiagnosed. Patients with FH are often under-
treated, but with early detection, cascade family testing and adequate treatment, patient outcomes 
can improve. Patient registries are key tools for providing new information on FH and enhancing 
care worldwide. The development and design of the FH Australasia Network Registry is a crucial 
component in the comprehensive model of care for FH, which aims to provide a standardized, high-
quality and cost-effective system of care that is likely to have the highest impact on patient outcomes. 
Informed by stakeholder engagement, the FH Australasia Network Registry was collaboratively 
developed by government, patient and clinical networks and research groups. The open-source, web-
based Rare Disease Registry Framework was the architecture chosen for this registry owing to its 
open-source standards, modular design, interoperability, scalability and security features; all these are 
key components required to meet the ever changing clinical demands across regions. This paper pro-
vides a high level blueprint for other countries and jurisdictions to help inform and map out the crit-
ical features of an FH registry to meet their particular health system needs. 
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Introduction
Familial Hypercholesterolaemia
Familial Hypercholesterolaemia (FH) is a rela-
tively common genetic disorder that is associated with 
premature coronary heart disease (CHD)1, 2). FH is 
the most common and serious monogenic disorder of 
lipoprotein metabolism, and causes severe elevation of 
total and low-density lipoprotein cholesterol (LDL-C) 
levels from birth3, 4). Heterozygous FH (HeFH) occurs 
in as many as 1 in 200 people2), while the prevalence 
of homozygous FH (HoFH) has recently been esti-
mated to be as high as 1 in 160,000–300,000 people5) 
for most populations. Higher frequencies of FH occur 
in first-degree relatives (1 in 2) of index cases, and in 
populations subject to a “founder gene effect,” such as 
Afrikaners and Ashkenazi Jews4).
Under-diagnosis of FH is a problem worldwide, 
with estimates of FH affecting as many as 34.3 mil-
lion people, with ＜1% of cases diagnosed in most 
countries6, 7). This represents a major gap in care, as 1 
in 2 untreated men and 1 in 6 untreated women 
develop fatal CHD by the age of 60 years. Early diag-
nosis and treatment can delay the manifestation of 
atherosclerosis, with the introduction of statins 
improving the life expectancy of patients with FH 
which now approaches that of the general population. 
However, the standardized mortality rate for CHD 
still remains higher8, 9). HoFH requires therapeutic 
intervention within the first decade of life due to the 
development of aggressive CHD during childhood 
and adolescence, without which they will generally 
sustain a fatal myocardial infarction before the age of 
30 years10). 
In Australia, at least 65,000 people are estimated 
to have FH with the vast majority undiagnosed, and 
in many diagnosed cases, patients are receiving inade-
quate treatment1, 11). The Western-Pacific and South-
East Asia regions have the highest estimated popula-
tion density of FH in the world12). Cascade family 
screening, by which all first-degree relatives of identi-
fied index patients are screened for FH, is of critical 
importance for early diagnosis and treatment of FH to 
delay or prevent the onset of premature CHD, yet is 
not often widely performed13). Only three national 
genetic cascade screening programs are currently oper-
ating in the Netherlands, Spain, and Wales, while 
advanced regional and local programs are operating in 
a number of countries including Australia, New Zea-
land, Slovenia, Czech Republic, and Malaysia14).
To bridge this major gap in CHD prevention, 
the Commonwealth Government funded a flagship 
program under the Australian Better Health Initiative 
(ABHI), that resulted in the development of models 
of care for FH in Western Australia (WA)15). Building 
on a WA health model of care, the FH Australasia 
Network published a comprehensive model of care for 
FH with the aim to provide a standardized, high-qual-
ity, and cost-effective system of care that is likely to 
have the highest impact on patient outcomes11), which 
was followed by the integrated guidance of care for 
FH by the International FH Foundation16). One 
important feature identified as essential to the imple-
mentation and effective provision of services, is a 
patient registry to store clinical and family data13, 15, 17). 
 
The Importance of Registries 
Patient registries capture relevant patient infor-
mation, including clinical and molecular information. 
Registries are clinical, information rich resources that 
are essential for the integration of research into clinical 
practice and translation into therapeutic solutions18). 
In populations with chronic disease, it has been dem-
onstrated that patient outcomes improve with the use 
of models of care that integrate patient and clinical 
information with evidence-based treatments19, 20). As 
such, the American Heart Association has called for an 
expansion of clinical registry programmes21). A recent 
review of current studies of FH patients also con-
cluded that complete national and international FH 
registries are key instruments for providing new infor-
mation on FH and enhancing the care of FH patients 
worldwide22). 
Over the last 30 years, several national FH regis-
tries (Table 1) and cascade screening programs have 
been established in various countries, most notably in 
the United Kingdom (The Simon Broome Register23, 24, 25) 
and The National Paediatric FH Register26)), the 
Netherlands (Dutch Lipid Clinic Network27)), Nor-
way (Registry of the Medical Genetics Laboratory28)/
Unit of Cardiac and Cardiovascular Genetics Regis-
try29, 30)), the United States (CASCADE FH31, 32) and 
MED-PED33)), Canada (British Columbia FH Regis-
try 34)), and Spain (SAFEHEART Study 35, 36)). 
Recently, the importance of establishing regional FH 
registries has been noted for the Middle Eastern and 
North African Region37), and France has also recently 
created a cohort of FH patients from across the coun-
try38). The European Atherosclerosis Society (EAS) 
recently launched a global “call to arms” initiative to 
integrate efforts from major FH registries around the 
world to generate large-scale data on the detection and 
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Table 1. Details of existing FH Registries
Type: DNA positive indicates a molecular genetic diagnosis of FH. Clinical indicates a clinical diagnosis of FH by DLCNS or other criteria. 
Hybrid indicates a mixture of molecular genetic and clinical diagnosis for inclusion in the registry.
Country/
Region
Registry Type Time-
frame
Number 
(year confirmed)
System Further details
UK The Simon Broome Register 
of FH23-25)
Hybrid 1980- 3,382 heFH patients from 
21 lipid clinics
SPSS Developed the Simon Broome Criteria to 
determine definite or probable FH status. 
Reported significant decreases in excess coronary 
heart disease mortality for patients who received 
early diagnosis and treatment. 
USA Make Early Diagnosis, 
Prevent Early Deaths 
(MEDPED)33)
Hybrid 1989-
2004
~8,000 definite or probable 
FH patients31)
MEDPED criteria created and validated to 
estimate the probability of FH. 
Norway Unit of Cardiac and 
Cardiovascular Genetics 
Registry28-30)
DNA 
positive
1992- 7,091 (2016) Filemaker from Apple Registry data can be linked to several other National 
health registries to assess mortality, cardiovascular 
disease and pregnancy outcomes in FH patients.
The Netherlands Dutch Lipid Clinic 
Network27)
Hybrid 1994- ＞30,00031) PASS Clinical ® 
Vascular
Developed and validated a set of diagnostic criteria 
for FH.
Czech Republic Czech MED-PED Registry Hybrid 1998- 6919 (2016) Online database 
(PAGEWISER)
MedPed project initiative.
Spain Spanish FH Longitudinal 
Cohort Study 
(SAFEHEART)35, 36)
Hybrid 2004- 4,615 (2016) Dinahosting (network 
server)
Approximately 3,000 individuals have a positive 
genetic test. The registry is run by the Fundación 
HF. Website: https://www.colesterolfamiliar.org/
Wales and 
England
Pass Database54, 55) Hybrid 2010- 2587 (2016) PASS Clinical ® 
Vascular
UK The National Paediatric FH 
Register26)
Clinical 2012- 380 (2016) Electronic data capture Established to collect baseline and long-term 
follow-up data on all children (0-18 years) with 
FH in the UK. Approximately 60% have a DNA 
family mutation recorded.
USA CASCADE FH31, 32) Hybrid 2013- 3,030 (2016) Bespoke built in 
partnership with the 
Duke Clinical Research 
Institute.
A nat ional ,  mult icentre  ini t iat ive  that 
longitudinally tracks FH therapy, family screening, 
clinical outcomes and patient-reported outcomes. 
Canada FH Canada Registry34) Hybrid 2014- 738 (2016); 2900 expected 
by the end of 2016
iCAPTURE (bespoke 
built) from the James 
Hogg Research Centre, 
UBC
Started in 2014 from the existing British 
Columbia FH Registry6). Established to diagnose, 
educate and treat individuals with heFHheFH. 
Website: www.fhcanada.net
France French Cohort of patients 
with FH38)
Clinical 2015- ~3,263 (2016) Integralis Primary objective is to create a cohort of French patients 
with FH to evaluate screening and clinical management.
Taiwan Taiwan Familial 
Hypercholesterolemia 
Registry Study
Hybrid 2015- 500 (2016) Clinical Study 
Information System 
(CIMS)
Organised by the Taiwan Society of Lipid & 
Atherosclerosis.
International European Atherosclerosis 
Society (EAS) FH Studies 
Collaboration (FHSC)39, 56)
Hybrid 2015- Data to be received from 
10/2016.
Bespoke system A global initiative from the EAS that, through a 
consortium of major FH registries worldwide, aims 
to generate large-scale robust data. Investigators 
from over 5 countries have formally committed to 
contribute their data to date.
International Homozygous autosomal 
dominant hypercholsterolemia 
(HoADH) International 
Clinical Collaboration (HICC) 
Hybrid 2015- REDCap The HICC will evaluate the true prevalence and 
phenotypic and genetic characterisation of 
HoADH. 
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management of FH (EAS FH Studies Collaboration 
(FHSC)39)).
Bamimore et al.37) noted that there is no “stan-
dard rule” for building a FH registry; however, they 
suggest following the consensus-based guidance for 
the management of FH16) as the starting point. A 
number of public and commercially available systems 
have been utilized in the creation of FH registries to 
date (see Table 1 for an overview). For example, PASS 
Clinical Vascular is a commercially available software 
package for clinical management and cascade screen-
ing, used in Latvia, Germany, Ireland, the United 
Kingdom, and the Netherlands40). REDCap is a web-
based application for building and managing online 
surveys and databases that is free to non-profit organi-
zations that are members of the REDCap consor-
tium41), used in some Japanese Atherosclerosis Society 
registry projects.
Registry Design
There are several fundamental factors that need 
to be considered when designing a registry including 
purpose, ethical and legal requirements, documenta-
tion, governance, design, and sustainability42). With a 
wide range of bespoke, commercially available, and 
open source tools available for the establishment of 
registries, choosing which system to use can be diffi-
cult due to the diverse range of functionality and tech-
nology choices offered18). 
To this point, several groups have recently devel-
oped key criteria for robust and sustainable registry 
implementation including, the Joint Declaration of 10 
Key Principles for Rare Disease Patient Registries 
issued by the European Organisation for Rare Diseases 
(EURORDIS), the National Organisation for Rare 
Diseases (NORD), and the Canadian Organization 
for Rare Disease (CORD)43), the recommendations 
published by the European Union Committee of 
Experts on Rare Diseases44), and Rare Disease and 
Patient Registry Checklists to guide future registry 
development18, 45, 46).
These recommendations and checklists highlight 
the effective sharing of data, and the ability to link 
patients, samples, and analyses are essential to the suc-
cess of disease research and improving outcomes for 
patients. This has led to international initiatives to 
harmonize legacy systems such as the European Union 
Framework Program 7, RD-Connect (http://rd-con-
nect.eu/), established to develop an integrated plat-
form that connects key infrastructure tools such as 
databases, registries, biobanks, and clinical bioinfor-
matics47). 
The open-source Rare Disease Registry Frame-
work (RDRF) was therefore developed as a viable 
solution to registry development18, 48-50). Rather than 
focusing on the deployment of single, stand-alone reg-
istries, the RDRF enables the dynamic creation of 
web-based patient registries without the need for soft-
ware development18, 48-50). By incorporating key crite-
ria required for a registry such as modular design, 
interoperability, and security features, the RDRF 
allows the deployment of national and international 
registries that are able to meet ever-changing clinical 
demands. 
Aim
This paper details the development and design of 
the FH Australasia Network Registry utilizing the 
RDRF. It provides a high level blueprint for other 
countries and jurisdictions to help inform and map 
out the critical features of a FH registry to meet their 
particular health system needs. The primary purpose 
of the FH Australasia Network Registry is to collate 
data to facilitate clinical service planning and to 
inform clinical best practices17). The registry will also 
enable research on aggregated data and the identifica-
tion of eligible volunteers for clinical trials. The spe-
cific aims include: 
1. Facilitate data collection to inform best prac-
tices, models of care, and health service planning;
2. Data analyses and reporting by the registry on 
estimated prevalence; geographical distribution, 
genetic variants associated with disease, clinical fea-
tures, clinical management and patient outcomes;
3. Enable research by providing aggregate, de-
identified data to research entities;
4. Facilitate identification and recruitment of eli-
gible volunteers for clinical trials; and
5. Coordinate and administer education to regis-
trants and participating centers.
Methods 
Development of the FH Australasia Network Registry 
Extensive stakeholder engagements led to the 
recognition of the need to improve outcomes for Aus-
tralian and New Zealand FH patients under the 
ABHI. This resulted in the establishment of clinical 
models of care11, 15) and the development of a simple 
relational database. Through an iterative process, an 
international registry previously titled the “Australia 
and New Zealand FH Registry (ANZFHR)”17) was 
developed. The registry was collaboratively developed 
by the Office of Population and Health Genomics 
(Department of Health, Government of Western Aus-
tralia), the FH Australasia Network (Australian Ath-
erosclerosis Society), clinical networks, and the Centre 
FH Australasia Network Registry 
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for Comparative Genomics (Murdoch University)13, 17). 
The Registry Framework
The RDRF allows the efficient deployment of 
web-based registries that can be modified dynamically 
as registry requirements evolve18, 48-50). The RDRF not 
only facilitates the effective capture, storage, manage-
ment, and access of patient information, it is designed 
to be interoperable to capture, import, and store data 
from other systems such as the RD-Connect plat-
form49) (see Fig.1). The ability to re-use data elements 
(DEs) across multiple registries greatly assists with the 
standardization of data capture, allowing for effective 
data sharing for research purposes. 
The RDRF fulfills the key criteria required for 
sustainable registry development18, 43, 44, 46), has continued 
to evolve since first described by Bellgard et al.18, 48-50). 
Additional features and enhancements of the RDRF 
were implemented specific to the FH Australasia Net-
work Registry, described in Napier et al.51).
Modular Design
The modular design of the RDRF enables simple 
configuration and creation of DEs, Sections, and 
Forms, such that FH Australasia Network Registry can 
continue to evolve over time. Currently, the patient 
data captured by the registry includes demographics 
and clinical information for each patient captured by 
the “Demographics” and “Consents” modules and six 
additional Forms titled Clinical Data, Medications, 
Genetic Data, Imaging, Apheresis and Follow Up 
(Table 2, also see Napier et al.51)).
 
Interoperability
The ability for patient registries to communicate 
and share data with systems such as other registries or 
Fig.1. The Rare Disease Registry Framework (RDRF) is a cloud-technol-
ogy based platform that is focused on analytics
The RDRF facilitates the capture of information in the form of patient registries 
or clinical trials through the capture and storage of data (demographics, geno-
typic and phenotypic), which then in turn informs knowledge such as clinical 
decisions (diagnosis, treatment, and patient support). The RDRF is designed to 
“talk” and connect to other systems such as biobanks, registries and Electronic 
Health Records to capture data and ultimately provide decision support.
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biobanks is critical. Interoperability in the RDRF is 
achieved through an application programming inter-
face (API), which can interrogate other systems via 
their API’s. In addition, the RDRF is able to share and 
re-use DEs, sections, and forms across multiple regis-
tries, assisting in the standardization of data capture.
Security
The RDRF provides distinct levels of inbuilt 
security, including Secure Socket Layer security 
encrypting all web traffic to and from the application, 
Cross-Site Request Forgery checking (a method of 
ensuring falsifying form submissions are near impossi-
ble), and the storage of identifying patient demo-
graphic data in a distinct database to any clinical data 
(refer to Napier et al.51))18, 48, 50). In addition, all user 
log-ins (successful and failed) are also recorded within 
the RDRF. The RDRF also has multiple levels of 
access with configurable permission levels (role based 
security model), which restricts the visibility of forms 
and fields to specified user groups. 
Governance and Access
Standard international ethical principles52), sup-
plemented by local legislation and requirements, were 
followed when initiating and deploying the FH Aus-
tralasia Network Registry. The FH Australasia Net-
work Registry is hosted and maintained at Murdoch 
University, WA, with strategic direction and oversight 
provided by an advisory board of key stakeholders (FH 
Australasia Network Registry Advisory Board). A char-
ter, protocol, and guidelines for the registry were 
developed by the WA Department of Health in con-
junction with the FH Australasia Network and Aus-
tralian Atherosclerosis Society, and are available from 
https://fhregistry-international.com.
The FH Australasia Network Registry is a multi-
center collaboration, coordinated through the FH 
Australasia Network, with a national coordinator 
responsible for ensuring cross-site coordination. A 
principal investigator from each State or jurisdictional 
clinical service is responsible for the data collation of 
their patients. Applications for access to data are con-
sidered for approval by the FH Australasia Network 
Registry Advisory Board.
Table 2. Capture of patient data in the FH Australasia Network Registry
FORM NAME SUMMARY
Consents Customisable consent sections easily allow new consent questions to be added or existing questions to be amended. 
Consent is captured via boolean Data Elements (DEs) presented as check boxes. A file DE allows the upload of a hard 
copy of a consent document if required.
Demographics Patient’s personal and contact details are captured, along with details of their doctors. For Index Patients, a Patient 
Relatives section is also present, which stores the details of relatives and allows a Patient Relative to be created in the 
registry. A Pedigree section allows the upload of family pedigree files and the capture of details on founder effect origin 
and the number of first, second and third degree relatives. The family linkage module, which details the relationships 
of Patient Relatives to Index Patients, is also accessed from this form.
Clinical Data Clinical data is captured through various DEs, including family history, clinical history, physical examination, plasma 
LDL-cholesterol, biochemistry profile, risk factors and clinical trials. Derived DEs are utilised which allow automatic 
calculations of the ‘Dutch Lipid Clinic Network Score’, ‘FH Diagnostic category’, ‘LDL-cholesterol adjusted for 
treatment’, and ‘BMI’. 
Medications Details on patient’s medications and drug intolerances are captured. Multi-sections, which allow the addition of the 
same section, are utilised to add additional drug intolerances if required.
Genetic Data This form captures a patient’s genetic data, such as the genotype and gene variants. Laboratory Reports can also be 
uploaded to the registry through the use of a file DE. 
Imaging This form captures details of various imaging tests, such as carotid ultrasonography, echocardiograms, coronary artery 
calcium scores, angiograms, and nuclear perfusion scans. Multi-sections are utilised so additional tests may be easily 
added as required.
Apheresis This form captures the type, frequency and complications related to apheresis through a multi-section.
Follow-Up This form captures additional clinical data at follow up assessments, such as events, hypertension, diabetes, 
antithrombotic, biochemistry profiles, and death.
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Discussion
In this paper, we describe the development and 
design of an international clinical registry for FH in 
Australia and New Zealand, the FH Australasia Net-
work Registry. The open-source nature and modular 
design of the RDRF, upon which the registry is 
deployed, contributes to its long-term sustainability. A 
key merit of the RDRF is that is has an open-source 
license (GNU GPL v3), which allows it to be freely 
shared. The RDRF is therefore more flexible as it is 
not bound by licensing agreements like other registry 
systems such as PASS Clinical Vascular and REDCap. 
The RDRF is also much more cost effective in com-
parison to commercial software such as PASS Clinical 
Vascular. New features can also be easily incorporated 
into an existing registry as they are made available, 
which allows for the continual evolution over time as 
required. For example, a dynamic application to draw 
patient pedigrees based on the diagnosis status and 
relationships of patients can be designed and imple-
mented in a future release of the RDRF. 
The FH Australasia Network Registry also pro-
vides a great opportunity for recruiting participants 
and planning clinical trials. Information can be easily 
gathered for future clinical trials, simply by defining a 
new “Clinical Trials” form and DEs customized to 
capture the appropriate data in the RDRF. Existing 
features, as well as DEs and sections defined for the 
FH Australasia Network Registry, can also be utilized 
and shared by other registries. The RDRF has been 
endorsed by RD-Connect (see: http://rd-connect.eu/
tools-resources/rare-disease-registry-framework-rdrf/), 
which emphasizes the value and long-term sustainabil-
ity of the RDRF, and its ability to be interoperable 
with other registries and systems.
Through its multi-level user access, the FH Aus-
tralasia Network Registry also has the ability to easily 
convert to a multi-national FH registry. As additional 
countries from across the Australasia-Pacific region 
join this registry, access will be easily configured 
through the use of customizable working groups and 
user permissions.
The FH Australasia Network Registry, deployed 
utilizing the RDRF, is a secure and comprehensive 
clinical registry that allows harmonization of data col-
lection across different states, clinical jurisdictions, 
and countries. The RDRF is highly interactive and 
flexible, and has the ability to connect to other regis-
tries, systems, and data repositories, thus distinguish-
ing the FH Australasia Network Registry from other 
FH registries developed to date. The full potential of 
this registry will be realized through its ability to con-
nect with other data linkage systems. 
The FH Australasia Network Registry has many 
functions. It is not only a repository of data, it also 
serves to support clinicians, researchers and patient 
groups, enables improvements to models of care, edu-
cation, and communication, and helps focus and drive 
research and the development of new treatments.
Conclusion
The features described and the processes articu-
lated in the development of the FH Australasia Net-
work Registry encompasses the key features that 
should be considered when choosing a system for 
building patient registries. The FH Australasia Net-
work Registry can be readily adapted to other condi-
tions related to FH, such as familial combined hyper-
lipidemia and elevated lipoprotein(a)53). This frame-
work is also applicable to other inherited cardiovascu-
lar conditions, such as familial hypertrophic cardio-
myopathy.
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